Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative™ announced the first patient has been dosed in their clinical trial evaluating Atossa’s proprietary-endoxifen in combination with abemaciclib, a cyclin-dependent kinase 4/6 inhibitor marketed by Eli Lilly and Company, as a neoadjuvant treatment in high-risk women with newly diagnosed Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer.